About binimetinib
MEK inhibitor anticancer medicine
Used for
- Treats certain advanced melanoma with an abnormal BRAF gene, with encorafenib.
Usual adult dose
45 mg by mouth twice daily with encorafenib; dose may be reduced for side effects.
Common side effects
- Diarrhea, nausea, vomiting, and abdominal pain
- Tiredness and muscle pain
- Rash and swelling
- Changes in heart function, vision, or liver tests
Important warnings
- Used with encorafenib; treatment requires specialist monitoring.
- Can cause serious heart, eye, muscle, liver, or lung problems.
- May cause bleeding or blood clots.
- Avoid pregnancy; effective contraception is important during treatment.
Pregnancy
May harm an unborn baby; human pregnancy data are limited.
Breastfeeding
Breastfeeding is not recommended during treatment or for three days after the last dose.
Interactions
- Encorafenib is used with binimetinib and affects treatment dosing.
- Tell the treatment team about all medicines and supplements; interactions may affect safety or effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.